Hashimoto, Kenji http://orcid.org/0000-0002-8892-0439
Funding for this research was provided by:
Japan Society for the Promotion of Science London (17H04243)
Japan Society for the Promotion of Science (19H05203)
Japan Agency for Medical Research and Development (JP20dm0107119)
Article History
Received: 24 November 2020
Accepted: 19 December 2020
First Online: 5 January 2021
Compliance with ethical standards
:
: Dr. Hashimoto is the inventor of filed patent applications on “The use of <i>R</i>-ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “<i>R</i>-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. Hashimoto received speaker honoraria from Abbott China. Dr. Hashimoto has received the research support from Dainippon Sumitomo, Otsuka, and Taisho.
Free to read: This content has been made available to all.